Oral Vaccination Protects Against Severe Acute Respiratory Syndrome Coronavirus 2 in a Syrian Hamster Challenge Model.

Autor:	Johnson S; Vaxart, South San Francisco, California, USA., Martinez CI; Vaxart, South San Francisco, California, USA., Tedjakusuma SN; Vaxart, South San Francisco, California, USA., Peinovich N; Vaxart, South San Francisco, California, USA., Dora EG; Vaxart, South San Francisco, California, USA., Birch SM; Lovelace Biomedical Research Institute, Albuquerque, New Mexico, USA., Kajon AE; Lovelace Biomedical Research Institute, Albuquerque, New Mexico, USA., Werts AD; Lovelace Biomedical Research Institute, Albuquerque, New Mexico, USA., Tucker SN; Vaxart, South San Francisco, California, USA.
Jazyk:	angličtina
Zdroj:	The Journal of infectious diseases [J Infect Dis] 2022 Jan 05; Vol. 225 (1), pp. 34-41.
DOI:	10.1093/infdis/jiab561
Abstrakt:	Background: Vaccines that are shelf stable and easy to administer are crucial to improve vaccine access and reduce severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission around the world. Methods: In this study, we demonstrate that an oral, adenovirus-based vaccine candidate protects against SARS-CoV-2 in a Syrian hamster challenge model. Results: Hamsters administered 2 doses of VXA-CoV2-1 showed a reduction in weight loss and lung pathology and had completely eliminated infectious virus 5 days postchallenge. Oral immunization induced antispike immunoglobulin G, and neutralizing antibodies were induced upon oral immunization with the sera, demonstrating neutralizing activity. Conclusions: Overall, these data demonstrate the ability of oral vaccine candidate VXA-CoV2-1 to provide protection against SARS-CoV-2 disease. (© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu